NDAINTRAVENOUSPOWDER
Approved
Jun 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pemetrexed ditromethamine is an intravenous powder formulation of pemetrexed, a multitargeted antifolate antimetabolite used in oncology. It is administered as a chemotherapy agent for certain solid tumors, including non-small cell lung cancer and mesothelioma. The drug works by inhibiting multiple folate-dependent enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in rapidly dividing cancer cells.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), indicating stable commercial operations and established field presence.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings suggests this product operates with an established, stable team structure. Roles on this asset would focus on defending market share in a competitive oncology space and managing clinical/commercial operations for an approved chemotherapy.
Brand ManagerMedical Science Liaison
Worked on PEMETREXED DITROMETHAMINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.